Application of CELSR2 gene as target spot in preparation of product for diagnosing and / or treating glioma

By knocking down the expression of CELSR2 gene or protein, interfering RNA technology is used to inhibit the proliferation and growth of glioma cells, solving the problem of glioma treatment, providing new biomarkers and targeted treatment methods, significantly improving the therapeutic effect .

CN118903427APending Publication Date: 2024-11-08UNIVERSITY OF HEALTH & REHABILITATION SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411001264.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The treatment of glioma is difficult to effectively inhibit its high invasiveness and recurrence, and there is a lack of effective biomarkers and targeted therapeutic methods.

Method used

By knocking down the expression of the CELSR2 gene or CELSR2 protein, small interfering RNA, shRNA, gRNA and other technologies are used to inhibit its biological function, block the Wnt/β-catenin pathway, reduce the levels of β-catenin and cyclin D1, and thus inhibit glioma Proliferation and growth of cells.

Benefits of technology

Effectively inhibit the proliferation and growth of glioma cells, significantly slowing down the tumor growth rate, providing new biomarker targets for diagnosis and prognosis evaluation, and improving the effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903427A_ABST
    Figure CN118903427A_ABST
Patent Text Reader

Abstract

The invention provides application of a CELSR2 gene as a target spot in preparation of a product for diagnosing and / or treating glioma, and belongs to the technical field of biological medicine. The invention provides application of a CELSR2 gene and / or CELSR2 protein as a target spot in preparation of a drug for treating glioma or a reagent or a kit for diagnosing glioma and / or evaluating the prognosis effect of glioma. Experiments show that the CELSR2 gene expression in a glioma clinical sample and a glioma cell line is increased, and the proliferation and tumor growth of glioma cells can be inhibited by knocking down the expression level of the CELSR2 gene or CELSR2 protein under in-vitro and in-vivo conditions. The technical scheme provided by the invention provides a new means for clinical diagnosis and treatment of glioma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of CELSR2 gene as a target in the preparation of products for diagnosing and / or treating gliomas. Background Art

[0002] Glioma is the most common primary brain tumor originating from glial cells, and its mortality rate is second only to pancreatic cancer and lung cancer. [1,2] , which is characterized by high invasiveness, difficulty in complete resection, frequent recurrence and poor prognosis, which seriously affect the quality of life of patients and impose a heavy burden on patients, families and society. According to the 2016 World Health Organization (WHO) classification, gliomas are divided into four grades, of which grade 1 and grade 2 gliomas are low-grade gliomas, and grade 3 and grade 4 gliomas are high-grade gliomas (HGG). [3] . The overall prognosis of brain glioma is related to many factors such as patient age, basic condition, tumor grade, tumor location, degree of resection, molecular variation, treatment response, and social family. In recent years, with the continuous deepening of research on the basic and clinical characteristics of gliomas, the field of brain gliomas has also been further developed. According to the 2021 WHO classification of central nervous system tumors, gliomas are highly heterogeneous and are mainly diagnosed by tissue characteristics and biomarkers. The standard emphasizes the significance of molecular pathological characteristics in glioma classification and treatment, and also provides ideas for finding new therapeutic targets. [4] At the same time, the study of tumor occurrence and development mechanism can also provide reference for the selection of therapeutic targets, so as to develop more effective and safe targeted drugs. Therefore, specific biomarkers are very important for the diagnosis and targeted treatment of glioma.

[0003] The Cadherin EGF LAG Seven-Pass G-Type Receptor 2 (CELSR2) gene encodes an atypical cadherin receptor protein with seven transmembrane segments. It is one of the core members of planar tissue polarity genes and is involved in multiple biological processes of neural development. [5] Previous studies have shown that CELSR2 is widely expressed in neurons and astrocytes in mice and humans. [6,7] . Currently, there are few studies on the expression and role of CELSR2 in tumors. Studies have shown that increased expression of CELSR2 in hepatocellular carcinoma is significantly correlated with the overall survival (OS) of HCC patients. Downregulation of CELSR2 can inhibit the proliferation and invasion of HCC cells and can be regarded as an independent risk factor for HCC patients. [8] The expression of CELSR2 is significantly increased in breast cancer and negatively correlated with overall survival (OS) [9] However, its expression and function in gliomas remain unclear.

[0004] References

[0005] 1. Medical Administration Bureau of the National Health Commission., Chinese Anti-Cancer Association Glioma Professional Committee., Chinese Medical Doctor Association Glioma Professional Committee. Guidelines for the diagnosis and treatment of glioma (2022 edition)[J]. Chinese Journal of Neurosurgery. 2022.38(8):757-777.

[0006] 2.Ostrom, QT, Price, M., Neff, C., Cioffi, G., Waite, K.A., Kruchko, C. and Barnholtz-Sloan, JSCBTRUS Statistical Report: Primary Brain and Other CentralNervous System Tumors Diagnosed in the United States in 2015-2019.NeuroOncol.2022.24(Suppl 5):v1-v95.3. Yu MW, Quail DF. Immunotherapy for Glioblastoma: Current Progress and Challenges. Front Immunol 2021;12:782687.

[0007] 3. Louis, DN, Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, WK, Ohgaki, H., Wiestler, OD, Kleihues, P. and Ellison, DW The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol.2016.131(6):803-820.

[0008] 4.Louis DN,PerryA,Wesseling PA-O,et al.The 2021WHO Classification ofTumors of the Central Nervous System:a summary.Neuro Oncol

[0009] 2021; 23(8): 1231 - 1251.

[0010] 5. Tissir F, Qu Y, Fau - Montcouquiol M, Montcouquiol M Fau - Zhou L, et al. Lack of cadherins Celsr2 and Celsr3 impairs ependymal ciliogenesis, leading to fatal hydrocephalus. Nat Neurosci 2010; 13(6): 700 - 707.

[0011] 6. Wen Q, Weng H, Liu T, et al. Inactivating Celsr2 promotes motor axon fasciculation and regeneration in mouse and human. Brain 2022; 145(2): 670 - 683.

[0012] 7. Liu A, Yu L, Li X, et al. Celsr2 - mediated morphological polarization and functional phenotype of reactive astrocytes in neural repair. Glia 2023; 71(8): 1985 - 2004.

[0013] 8. Xu M, Zhu S, Xu R, Lin N. Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. BMC Cancer 2020; 20(1): 313.

[0014] 9. Jiang L, Zhang X, Xiang C, et al. Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer. Histol Histopathol 2018; 33(8): 835 - 842. Summary of the Invention

[0015] In view of this, the object of the present invention is to provide an application of the CELSR2 gene as a target in the preparation of a product for diagnosing and / or treating gliomas. The CELSR2 gene is highly expressed in gliomas, and the growth of gliomas can be inhibited by knocking down the expression of CELSR2.

[0016] The present invention provides the use of CELSR2 gene and / or CELSR2 protein as a target in the preparation of a drug for preventing and / or treating glioma.

[0017] The present invention provides use of an agent for knocking down the expression level of CELSR2 gene and / or CELSR2 protein and / or an agent for inhibiting the biological function of CELSR2 protein in the preparation of a drug for preventing and / or treating glioma.

[0018] Preferably, the reagent for knocking down the expression level of CELSR2 gene and / or CELSR2 protein comprises at least one of the following reagents: small interfering RNA, shRNA, gRNA and a gene editing system comprising the gRNA;

[0019] The nucleotide sequence of the CELSR2 gene is shown in SEQ ID NO:1.

[0020] Preferably, the small interfering RNA comprises CELSR2-siRNA obtained by hybridization of a sense strand and an antisense strand;

[0021] The nucleotide sequence of the sense strand is shown in SEQ ID NO: 2;

[0022] The nucleotide sequence of the antisense strand is shown in SEQ ID NO:3.

[0023] Preferably, the shRNA includes CELSR2-shRNA obtained by hybridization of the first strand and the second strand;

[0024] The nucleotide sequence of the first strand is shown in SEQ ID NO:4;

[0025] The nucleotide sequence of the second chain is shown in SEQ ID NO:5.

[0026] Preferably, the agent for inhibiting the biological function of CELSR2 protein comprises a nucleic acid aptamer targeting CELSR2 protein and / or a CELSR2 protein inhibitor.

[0027] The present invention provides the use of CELSR2 gene and / or CELSR2 protein as a target in preparing a reagent or a kit for diagnosing glioma and / or evaluating the prognosis effect of glioma.

[0028] The present invention provides an application of a reagent for detecting the expression level of CELSR2 gene and / or CELSR2 protein in preparing a reagent or a kit for diagnosing glioma and / or evaluating the prognosis of glioma.

[0029] Preferably, the reagent for detecting the expression level of the CELSR2 gene includes a forward primer for qPCR amplification of the CELSR2 gene and a reverse primer for qPCR amplification of the CELSR2 gene;

[0030] The nucleotide sequence of the forward primer for qPCR amplification of the CELSR2 gene is shown in SEQ ID NO: 6;

[0031] The nucleotide sequence of the reverse primer for qPCR amplification of the CELSR2 gene is shown in SEQ ID NO:7.

[0032] Preferably, the reagent for detecting the expression level of CELSR2 protein comprises an antibody against CELSR2 protein.

[0033] The present invention provides the use of Celsr2 gene and / or CELSR2 protein as a target in the preparation of a drug for preventing and / or treating glioma. The present invention has found a gene target CELSR2 (NCBI ID: 1952) for treating glioma. Knocking down the expression of CELSR2 gene or protein in glioma cells by interfering RNA technology can effectively block the cell cycle in the G0 / G1 phase and inhibit cell proliferation. The embodiment of the present invention also confirmed that CELSR2 knockdown can inhibit tumor growth in a nude mouse glioma xenograft model. In terms of specific treatment mechanisms, knocking down the expression of CELSR2 gene inhibits the Wnt / β-catenin pathway, reduces the levels of β-catenin and cyclin D1, and causes cell cycle arrest. Down-regulation of CELSR2 expression leads to a significant slowing of the growth rate of glioma xenografts. It can be seen that CELSR2 is an important biological target for the treatment of gliomas, providing a treatment method for some glioma patients.

[0034] The present invention provides the use of CELSR2 gene and / or CELSR2 protein as a target in the preparation of a reagent or kit for diagnosing glioma. The present invention first verifies that the expression of CELSR2 gene in glioma tissue is higher than that in adjacent cancer tissue, and high expression is significantly correlated with the poor prognosis of glioma patients. After knocking down the CELSR2 gene, glioma cell proliferation and glioma growth are significantly inhibited. Therefore, the expression level of CELSR2 gene and / or CELSR2 protein can indicate the risk of glioma in patients, provide a new biomarker target for the diagnosis of glioma or the evaluation of glioma prognosis, and can accurately diagnose and evaluate the occurrence and development of glioma. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The expression of CELSR2 gene in glioma; A. Analysis results of TCGA, GTEx, and CGGA databases; B. KM survival curve of patients with primary glioma (WHO graded survival rate, n=202); C. KM survival curve of patients with recurrent glioma (WHO graded survival rate, n=127 or 126); D. RT-qPCR analysis of CELSR2 expression in glioma tissues and glioma cell lines of clinical patients; N, paracancerous tissue; T, tumor; CP-H122, normal astrocytes; E is the result of immunohistochemical staining, ****P<0.0001;

[0036] Figure 2 The effects of CELSR2 gene knockdown on the proliferation and cell cycle of glioma cells, including A. RT-qPCR detection of CELSR2 expression in cells with different treatments; B and C. Two-dimensional culture experiments showing the results of cell colony formation after U87 MG knockdown of CELSR2; D and E. Flow cytometry detection of cell cycle after PI staining, *P<0.05, **P<0.01; AC: n=3; D, E: n=5;

[0037] Figure 3 The proteomic characteristics of glioma cells altered by CELSR2 knockdown; A. The results of gene set enrichment analysis after DIA protein sequencing on the cell cycle; B. The volcano plot shows the results of up-regulated and down-regulated proteins in the CELSR2 KD group; C and D. Western blot verification of the expression of proliferation and cycle-related proteins, ***P<0.001, ****P<0.0001, n=3;

[0038] Figure 4 The results of the effect of CELSR2 gene knockdown on tumor growth, including A. Schematic diagram of the method of subcutaneous injection of U87MG or U87 MG with CELSR2 gene knockdown into nude mice; B and C. Growth results of U87MG cells with CELSR2 knockdown after tumor formation; D. Schematic diagram of the preparation of magnetic nanomaterials (siRNA MNPs) coupled with CELSR2-siRNA and the method of administration to nude mice; E and F. Effect of siRNA MNPs on tumor growth; **P<0.01, AC: n=5; DF: n=8. DETAILED DESCRIPTION

[0039] The present invention provides the use of CELSR2 gene and / or CELSR2 protein as a target in the preparation of a drug for preventing and / or treating glioma.

[0040] In the present invention, the expression of CELSR2 gene in glioma tissue is higher than that in adjacent tissue, and high expression is significantly correlated with poor prognosis of glioma patients. After knocking down CELSR2 gene expression or CELSR2 protein level, the proliferation of glioma cells is significantly inhibited, and glioma growth is inhibited under in vivo conditions. It can be seen that CELSR2 gene and / or CELSR2 protein play a role as a target in the prevention and / or treatment of glioma.

[0041] The present invention provides use of an agent for knocking down the expression level of CELSR2 gene and / or CELSR2 protein and / or an agent for inhibiting the biological function of CELSR2 protein in the preparation of a drug for preventing and / or treating glioma.

[0042] In the present invention, the reagent for knocking down the expression level of CELSR2 gene and / or CELSR2 protein preferably includes at least one of the following reagents: small interfering RNA, shRNA, gRNA and a gene editing system containing gRNA. The nucleotide sequence of the human CELSR2 gene is preferably as shown in SEQ ID NO: 1, and the accession number in NCBI is 1952. The present invention has no special restrictions on small interfering RNA, shRNA and gRNA, and the sequence that can effectively silence the target gene using the design principles known in the art can be used. In an embodiment of the present invention, the small interfering RNA preferably includes CELSR2-siRNA obtained by hybridization of the sense strand and the antisense strand. The nucleotide sequence of the sense strand is preferably as shown in SEQ ID NO: 2 (CCACUAUACAGUGAAUGUUAAdTdT); the nucleotide sequence of the antisense strand is preferably as shown in SEQ ID NO: 3 (UUAACAUUCACUGUAUAGUGGdTdT). In another embodiment of the present invention, the shRNA preferably includes CELSR2-shRNA obtained by hybridization of the first strand and the second strand. The nucleotide sequence of the first chain is preferably as shown in SEQ ID NO:4 (CCGGACTCGTCAGGCTCCGAATTTCCTCGAGGAAATTCGGAGCCTGACGAGTTTTTTG); the nucleotide sequence of the second chain is preferably as shown in SEQ ID NO:5 (AATTCAAAAAACTCGTCAGGCTCCGAATTTCCTCGAGGAAATTCGGAGC CTGACGAGT). The small interfering RNA and shRNA are preferably present in a form that is conducive to a large amount of stable entry into cells, for example, in the form of a magnetic nanocomplex coupled with siRNA. The reagent that inhibits the biological function of CELSR2 protein preferably includes a nucleic acid aptamer targeting CELSR2 protein and / or a CELSR2 protein inhibitor. The experimental results show that both CELSR2-siRNA and CELSR2-shRNA can effectively knock down the expression of the CELSR2 gene and the corresponding protein, and affect the proliferation and growth of glioma cells, thereby achieving the purpose of inhibition. The present invention does not impose any particular limitation on the types of nucleic acid aptamers targeting CELSR2 protein or CELSR2 protein inhibitors, and nucleic acid aptamers targeting CELSR2 protein and / or CELSR2 protein inhibitors known in the art can be used.

[0043] In the present invention, the drug has an agent for knocking down the expression level of CELSR2 gene and / or CELSR2 protein and / or an agent for inhibiting the biological function of CELSR2 protein as an active ingredient, and preferably also includes a pharmaceutically acceptable excipient. The present invention does not impose any special restrictions on the type of the excipient, and common excipients of gene drugs or chemical drugs known in the art can be used. The drug is preferably administered by intravenous or in situ injection. The dosage of the drug is administered according to the final concentration entering the cell. In an embodiment of the present invention, the shRNA administered to glioma cells is in the form of a virus containing CELSR2-shRNA, and the administration concentration is not less than 2×10 9 TU / ml, more preferably (3-10)×10 9 TU / ml, most preferably 5×10 9 TU / ml. Titer unit: TU / mL, refers to the number of biologically active virus particles contained in each milliliter. TU is the abbreviation of transducing units, which means the number of viral genomes that can infect and enter the target cells.

[0044] In the present invention, by knocking down the expression level of CELSR2 gene or CELSR2 protein, the proliferation of glioma cells can be effectively inhibited, the cell cycle can be blocked, and the cell cycle can be blocked in the G0 / G1 phase. At the same time, further DIA proteomics analysis and immunoblotting (Western blot) experimental results show that the expression of cell cycle and proliferation-related proteins cyclin D1 (CCND1), CCNB1 and SERPINE1 is significantly downregulated. Animal experiments show that compared with inoculated normal glioma cells, knocking down the expression level of CELSR2 gene or CELSR2 protein significantly reduces the in vivo growth rate of glioma and significantly reduces the tumor volume. It can be seen that the reagent for knocking down CELSR2 gene or CELSR2 protein is used in the treatment of glioma.

[0045] The present invention provides the use of CELSR2 gene and / or CELSR2 protein as a target in preparing a reagent or a kit for diagnosing glioma and / or evaluating the prognosis effect of glioma.

[0046] In the present invention, it is first verified that the expression of CELSR2 gene or CELSR2 protein in glioma clinical samples and glioma cell lines is significantly increased compared with adjacent tissues. Through in vivo and in vitro verification, compared with normal glioma cells, the knockdown of CELSR2 gene or CELSR2 protein inhibits glioma cell proliferation and tumor growth, and leads to cell cycle arrest. Therefore, CELSR2 gene and / or CELSR2 protein can be used as diagnostic targets for the diagnosis of glioma and / or the evaluation of glioma prognosis. When the expression of CELSR2 gene and / or CELSR2 protein is significantly increased, it indicates that the patient from which the sample is derived may have glioma or that the prognosis of glioma is poor. When the expression of CELSR2 gene and / or CELSR2 protein is not significantly changed compared with healthy cells, it indicates that the risk of glioma cells in the sample source population is lower or the prognosis of glioma is better.

[0047] The present invention provides an application of a reagent for detecting the expression level of CELSR2 gene and / or CELSR2 protein in preparing a reagent or a kit for diagnosing glioma and / or evaluating the prognosis of glioma.

[0048] In the present invention, the reagent for detecting the expression level of CELSR2 gene preferably includes a forward primer for qPCR amplification of CELSR2 gene and a reverse primer for qPCR amplification of CELSR2 gene. The nucleotide sequence of the forward primer for qPCR amplification of CELSR2 gene is preferably as shown in SEQ ID NO: 6; the nucleotide sequence of the reverse primer for qPCR amplification of CELSR2 gene is preferably as shown in SEQ ID NO: 7. When the reagent is prepared, the forward primer and the reverse primer are preferably dissolved in a solvent. The solvent is preferably TE liquid. When the kit is prepared, it is preferably also included with an internal reference gene amplification primer and a qPCR amplification premix. The reagent for detecting the expression level of CELSR2 protein preferably includes an antibody against CELSR2 protein. When the reagent is prepared, the antibody containing the anti-CELSR2 protein is dissolved in a solvent to obtain an antibody solution against CELSR2 protein. The solvent of the antibody against CELSR2 protein is a mixture of sterile double distilled water and glycerol in a volume ratio of 1:1. When the kit is prepared, the detection kit is preferably prepared based on the principle of antigen-antibody specific reaction. The detection kit is preferably prepared based on at least the following techniques: immunofluorescence, immunohistochemistry, immunoblotting and immunochromatography, etc. In the present invention, immunohistochemistry and immunoblotting methods are used to detect the expression level of CELSR2 protein in glioma.

[0049] The application of the CELSR2 gene provided by the present invention as a target in the preparation of products for diagnosing and / or treating gliomas is described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.

[0050] Example 1

[0051] Clarify the expression of CELSR2 gene in glioma clinical samples and glioma cell lines

[0052] In order to verify whether the CELSR2 gene is also involved in the occurrence of glioma, this example first studies the expression of the CELSR2 gene in glioma tissues of clinical patients. Download data from TCGA, GTEx, and CGGA databases for analysis: Enter the keywords "glioma" and "CELSR2" in the TCGA and GTEx related databases (https: / / xenabrowser.net / ?bookmark=2b707e21a992c2963e949b3e5241cc70), download the mRNA expression levels of CELSR2 in different types of gliomas and normal tissues, group them according to the requirements (normal group, primary, recurrence), import the data into GraphPad, and use the one-way ANOVA analysis of variance with Tukey's multiple comparison tests statistical method to draw a graph, and obtain Figure 1 In A, enter "CELSR2" in the CGGA database, select the survival curve, and get Figure 1 Figures B and C.

[0053] The results showed that the mRNA level of CELSR2 gene was significantly increased in primary and recurrent gliomas compared with adjacent adjacent tissues ( Figure 1 In patients with primary glioma and recurrent glioma, the survival rate of patients was negatively correlated with the expression of CELSR2 in glioma tissues ( Figure 1 B and C).

[0054] To confirm this result, glioma tissues and adjacent tumor tissues from patients in the Department of Neurosurgery of the First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital) were collected, and the expression level of CELSR2 gene mRNA was detected by RT-qPCR. The specific steps are as follows:

[0055] 1. qPCR amplification primers

[0056] CELSR2 forward primer F: 5′-AGTGGCATACGGTGCAGCTGAA-3′ (SEQ ID NO: 6);

[0057] CELSR2 reverse primer R: 5′-ACTCCTGTGTCACAGCCATCCA-3′ (SEQ ID NO: 7);

[0058] Internal reference gene GAPDH:

[0059] Forward primer F: GTCTCCTCTGACTTCAACAGCG (SEQ ID NO: 8);

[0060] Reverse Primer R: ACCACCCTGTTGCTGTAGCCAA (SEQ ID NO: 9).

[0061] 2. Amplification reaction

[0062] Table 1 Reaction system

[0063] Reagents Dosage 5xPrimeScriptRTMasterMix(PerfectRealTime) 2.0μl Total RNA 500ng <![CDATA[RNaseFreedH2O]]> Add to 10 μl

[0064] After preparing the reaction system, incubate at 37°C for 15 minutes (reverse transcription);

[0065] 85°C, 5 seconds (inactivation reaction of reverse transcriptase);

[0066] 4℃.

[0067] Table 2 Reaction system 2

[0068] Reagents Dosage TBGreenPremixExTaqII(2x) 12.5μl PCRForwardPrimer (10 μM) 1.0μl PCR Reverse Primer (10 μM) 1.0μl System 1 reaction solution (cDNA solution) 2.0μl Sterilized water 8.5μl total 25μl

[0069] Table 3 Reaction conditions

[0070]

[0071]

[0072] The results showed that the expression level of CELSR2 gene mRNA in glioma tissue was significantly higher than that in adjacent tumor tissue ( Figure 1 (middle D).

[0073] Immunohistochemical staining was used to detect the expression of CELSR2 protein in primary and recurrent glioma tissues. The results showed that the expression of CELSR2 protein in primary and recurrent glioma tissues increased ( Figure 1 Similarly, CELSR2 mRNA was significantly upregulated in two glioma cell lines (U87 and U251) compared with a normal astrocyte cell line (CP-H122) ( Figure 1 The above results preliminarily confirmed that CELSR2 expression is elevated in gliomas, and CELSR2 gene or CELSR2 protein may be a potential target for glioma treatment.

[0074] Example 2

[0075] In vitro cultured glioma cells, knocking down the expression of CELSR2 gene by CELSR2 shRNA inhibited the proliferation of glioma cells and caused cell cycle arrest.

[0076] Using the CELSR2 gene as a template, shRNA was designed, and the resulting DNA sequence of CELSR2-shRNA was as follows: first strand: CCGGACTCGTCAGGCTCCGAATTTCCTCGAGGAAATTCG GAGCCTGACGAGTTTTTTG, SEQ ID NO: 4;

[0077] Second strand: AATTCAAAAAACTCGTCAGGCTCCGAATTTCCTCGAGGAAAT TCGGAGCCTGACGAGT, SEQ ID NO:5.

[0078] The CELSR2-shRNA sequence obtained according to the above design was commissioned to Shanghai Quanyang Biotechnology Co., Ltd. for synthesis, and the recombinant lentivirus LV-CELSR2-shRNA was packaged using the viral recombinant vector pLVX-shRNA1-ZsGreen-puro.

[0079] In order to clarify the role of CELSR2 gene in glioma cell line (U87 MG), LV-CELSR2-shRNA (2×10 9 TU / ml) was transfected into U87 MG to knock down the expression of CELSR2 gene, and the knockdown efficiency was detected by the RT-qPCR method of Example 1 to obtain U87MG cells with low CELSR2 gene expression.

[0080] The results showed that the expression of CELSR2 mRNA in U87 MG transfected with LV-CELSR2-shRNA was significantly downregulated, but still higher than that in normal cells (CP-H122) ( Figure 2 (A).

[0081] Clone formation assay: U87 MG cells with CELSR2 gene knockdown and normal cells were cultured at 5×10 2 The cells were inoculated in a six-well plate at an inoculum size of 1 / well and cultured normally for 14 days. The cells were then fixed with 4% paraformaldehyde for 15 minutes and stained with 0.05% crystal violet for more than 1 hour. Colonies with a diameter greater than 200 μm were counted under a dissecting microscope. The results of the cloning assay showed that the number of colonies formed was significantly reduced after U87 MG knocked down CELSR2 (CELSR2 KD group) ( Figure 2 B and C).

[0082] In order to study whether CELSR2 gene knockdown affects the cell cycle, the results of flow cytometry after PI staining in this example showed that after U87 MG knockdown of CELSR2, the cell cycle changed, the number of cells in the S phase decreased, and the number of cells in the G0 / G1 phase increased ( Figure 2The above results confirmed that knockdown of CELSR2 gene or CELSR2 protein inhibited the proliferation of glioma cells and induced cell cycle arrest.

[0083] Example 3

[0084] Detection of the expression of cell proliferation and cell cycle-related proteins after CELSR2 protein knockdown by DIA quantitative proteomic sequencing

[0085] In order to further explore the effect of CELSR2 knockdown, this example conducted DIA proteomics to study the difference in protein expression between U87 MG cells with CELSR2 gene expression knockdown and normal cells, which was specifically commissioned to Guangzhou Kidio Biotechnology Co., Ltd.

[0086] Gene set enrichment analysis (GSEA) showed that the cell cycle of CELSR2 knockdown genes was significantly downregulated compared with the control group ( Figure 3 Middle A: NES = -1.409, FDR = 0.143); In the volcano plot of differential protein enrichment, it was found that cell cycle and proliferation-related proteins CCND1, CCNB1 and SERPINE1 were downregulated ( Figure 3 (B).

[0087] In order to verify the results of DIA proteomics, Western blot was used to verify the expression level of cyclinD1 (CCND1) in U87 MG cells with CELSR2 gene expression knocked down and normal cells. Western blot results showed that compared with the control group, cyclinD1 (CCND1) was significantly downregulated after CELSR2 knockdown ( Figure 3 C and D).

[0088] The above results indicate that knocking down the CELSR2 gene or CELSR2 protein level can inhibit cell proliferation and cell cycle-related proteins.

[0089] Example 4

[0090] Effect of knockdown of CELSR2 expression in subcutaneous glioma on tumor growth

[0091] To further verify the effect of knocking down the expression of CELSR2 gene or CELSR2 protein level on glioma growth in vivo, the following experiments were performed:

[0092] 1. Effect of knockdown of CELSR2 gene by CELSR2-shRNA on glioma growth in vivo

[0093] 5×10 6U87 MG cells transfected with CELSR2-shRNA (obtained by hybridization of SEQ ID NO: 4 and SEQ ID NO: 5) (CELSR2 KD group) were inoculated with an inoculum volume of cells / 100 μL, and a control group was also inoculated with normal U87 MG cells (U87 MG group) ( Figure 4 (A). 28 days after inoculation, tumor tissues were collected and tumor weights were measured. The results showed that compared with the control group, the tumor weight in the CELSR2 KD group was significantly reduced ( Figure 4 B and C).

[0094] 2. Effect of knockdown of CELSR2 gene by CELSR2-siRNA on glioma growth in vivo

[0095] 2.1 Preparation method of magnetic nanomaterials: Zinc-doped magnetic nanoparticles (MNPs) were prepared based on previous work (doi:10.1021 / nl301499u). First, 2.00mmol iron acetylacetonate and 1.3mmol zinc chloride were placed in a 100ml three-necked round-bottom flask, and 12.62mmol oleic acid, 24.32mmol oleylamine and 13.72mmol octyl ether were added. The mixed solution was then heated to 330°C and reacted for 1 hour under an argon environment. After cooling to room temperature, ethanol was added to the mixture, and MNPs formed a black precipitate. Then, the mixture was washed three times with ethanol and the MNPs were separated by a magnetic field. Finally, the MNPs were dispersed in toluene and stored at 4°C for the next step.

[0096] 2.2 Modification method of magnetic nanomaterials: In order to further improve the dispersibility and biocompatibility of MNPs, MNPs were converted from oil phase to water phase by surface double exchange. Briefly, 25 mg of citric acid (CA) was dissolved in 5 ml of deionized water, and 5 mg of MNPs were dispersed in 10 ml of ethanol. The MNPs ethanol solution was then placed under an ultrasonic probe for 90 min at an amplitude of 12%, and CA solution was added dropwise. The carboxylic acid functional group of CA has a strong tendency to coordinate with metals and is highly hydrophilic. The modified product (MNPs-CA) was washed three times with deionized water and collected by magnetic separation.

[0097] In order to endow MNPs with the ability to load siRNA, polyethyleneimine (PEI, Mw = 10000) was introduced. First, 5 mg of MNPs-CA was dispersed in 6 ml of deionized water, and 0.6 mmol of N-hydroxysuccinimide (NHS) and 0.5 mmol of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) were added to activate the carboxyl groups of MNMs and react them with the amino groups of PEI (MNPs-PEI). After reacting overnight, MNPs-PEI was washed 3 times with deionized water and stored at 4°C.

[0098] 2.3 Preparation of siRNA-coupled magnetic nanocomplexes

[0099] The modified magnetic nanomaterial prepared above was mixed with CELSR2-siRNA (sense strand: CCACUAUACAGUGAAUGUUAAdTdT, SEQ ID NO: 2; antisense strand: UUAACAUUCACUGUAUAGUGGdTdT, SEQ ID NO: 3) and incubated at room temperature for 30 min to obtain a stable siRNA-coupled magnetic nanocomplex (siRNA-MNPs, Figure 4 D) for future use.

[0100] 2.4 Animal medication and testing

[0101] The cultured U87 MG cell suspension (5×10 6 cells / 100μL) were injected subcutaneously into the left posterior part of the mouse. When the tumor volume increased to 100mm 3 The mice were injected with siRNA-coupled magnetic nanocomplexes (25 mg / kg / day, referred to as the siRNAMNPs group) through the tail vein at the same time. At the same time, two control groups were injected with magnetic nanomaterials at the same time and at the same dose (referred to as the MNPs group). The other control group was injected with saline (referred to as the control group). A magnet with a magnetic field of 0.5T was fixed on the tumor site of the mice for 24 hours for 7 consecutive days ( Figure 4 (D) 28 hours after administration, the mouse tumors were collected and weighed.

[0102] The results showed that the tumor weight in the siRNAMNPs group was significantly reduced compared with the control group and the MNPs group ( Figure 4 E and F).

[0103] It can be seen from the results of the above examples that the expression of CELSR2 gene and CELSR2 protein can be effectively knocked down by using CELSR2-shRNA or CELSR2-siRNA, thereby inhibiting the growth of glioma in vivo.

[0104] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of CELSR2 gene and / or CELSR2 protein as a target in the preparation of drugs for preventing and / or treating glioma.

2. Use of an agent for knocking down the expression level of CELSR2 gene and / or CELSR2 protein and / or an agent for inhibiting the biological function of CELSR2 protein in the preparation of a drug for preventing and / or treating glioma.

3. The application according to claim 2, characterized in that: The reagent for knocking down the expression level of the CELSR2 gene and / or CELSR2 protein comprises at least one of the following reagents: small interfering RNA, shRNA, gRNA, and a gene editing system comprising the gRNA; The nucleotide sequence of the CELSR2 gene is shown in SEQ ID NO:

1.

4. The use according to claim 3, characterized in that: The small interfering RNA includes CELSR2-siRNA obtained by hybridization of a sense strand and an antisense strand; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 2; The nucleotide sequence of the antisense strand is shown in SEQ ID NO:

3.

5. The application according to claim 3, characterized in that: The shRNA includes CELSR2-shRNA obtained by hybridization of a first strand and a second strand; The nucleotide sequence of the first strand is shown in SEQ ID NO:4; The nucleotide sequence of the second chain is shown in SEQ ID NO:

5.

6. The use according to claim 2, characterized in that: The reagent for inhibiting the biological function of CELSR2 protein includes nucleic acid aptamers targeting CELSR2 protein and / or CELSR2 protein inhibitors.

7. Use of CELSR2 gene and / or CELSR2 protein as a target in the preparation of reagents or kits for diagnosing glioma.

8. Use of a reagent for detecting the expression level of CELSR2 gene and / or CELSR2 protein in the preparation of a reagent or kit for diagnosing glioma and / or evaluating the prognosis of glioma.

9. The use according to claim 8, characterized in that: Reagents for detecting the expression level of the CELSR2 gene include a forward primer for qPCR amplification of the CELSR2 gene and a reverse primer for qPCR amplification of the CELSR2 gene; The nucleotide sequence of the forward primer for qPCR amplification of the CELSR2 gene is shown in SEQ ID NO: 6; The nucleotide sequence of the reverse primer for qPCR amplification of the CELSR2 gene is shown in SEQ ID NO:

7.

10. The use according to claim 8, characterized in that: The reagent for detecting the expression level of CELSR2 protein includes an antibody against CELSR2 protein.